Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas
- Conditions
- Cancer of Pancreas
- Registration Number
- NCT02682394
- Lead Sponsor
- Soroka University Medical Center
- Brief Summary
Prognostic Importance of Quantitative Magnetic Resonance Imaging for Evaluation of Pancreatic Steatosis in Patients with Pancreatic Cancer
- Detailed Description
1. Finding patients with pancreatic cancer (in all stages), before any treatment.
2. Non invasively quantify fatty infiltration of pancreas using, MRI DIXON Scan in pancreatic cancer patient relatively to liver.
3. Measuring cell-free blood DNA in those patients for evaluating the aggressiveness of the disease.
4. Quantify the prognostic significance of pancreatic steatosis in comparison with clinical and pathological prognostic indexes used today.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
- patients diagnosed with any pancreatic cancer, in any stage, before treatment.
- >18 y.o
- claustrophobia
- GFR<30
- patients with non mri compatible devices (e.g. orthopaedic external fixation system)
- After chemotherapy treatment or surgical procedure
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of fat in pancreas measured in the head, body and tail excluding the lesion area. at 24 hours before chemotherapy starting measuring Pancreatic Steatosis in patients with pancreatic cancer using MRI DIXON scan, at 24 hours before chemotherapy starting.
Blood levels of free DNA The blood sample taken 15 minutes prior to MRI study, at time of IV access. Correlation of free DNA level and metastatic spread.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Soroka university medical center
🇮🇱Beer Sheva, Israel